Pharmaceuticals Middle East

Middle East CAR-T Cell Therapy Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Middle East CAR-T Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Middle East · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $182.3 Mn Placeholder estimate
Estimate 2025 $227.1 Mn 3.5% of the global market
Projected 2034 $1.64 Bn 623.9% Adds $1.42 Bn over 9 forecast years
CAGR 2025–2034 24.6% Faster than 92% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Middle East is 3.52% of the global market.
  • Among regions, the largest is North America at $3.01 Bn.
  • Fastest growing: APAC at 25.4% a year.
  • Middle East ranks 5th of 6 by size among regions.

Market size projection

Middle East

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.42 Bn total, 2026–2034

Year-by-year market size, 2024–2034
CAR-T Cell Therapy Market market size by year, Middle East
YearMarket sizeChange that yearSince 2025
2024 (estimate) $182.3 Mn — —
2025 (base) $227.1 Mn +$44.8 Mn —
2026 (forecast) $283.0 Mn +$55.9 Mn +24.6%
2027 (forecast) $352.6 Mn +$69.6 Mn +55.3%
2028 (forecast) $439.4 Mn +$86.7 Mn +93.4%
2029 (forecast) $547.5 Mn +$108.1 Mn +141%
2030 (forecast) $682.1 Mn +$134.7 Mn +200.3%
2031 (forecast) $849.9 Mn +$167.8 Mn +274.2%
2032 (forecast) $1.06 Bn +$209.1 Mn +366.3%
2033 (forecast) $1.32 Bn +$260.5 Mn +481%
2034 (forecast) $1.64 Bn +$324.6 Mn +623.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Middle East CAR-T Cell Therapy Market Analysis at a glance
Market size, 2025$227.1 Mn placeholder estimate
Forecast, 2034$1.64 Bn placeholder estimate
Growth (CAGR), 2025–203424.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTarget, indication and end user (see all)
Key playersGilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson, Legend Biotech and 1 more (see all)
Active clinical trials10 in Middle EastSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Middle East CAR-T Cell Therapy Market Analysis Executive Summary

CAR-T cell therapy changes a patient's own immune T cells so they can find and kill cancer cells, mainly in blood cancers.

Key segments of the CAR-T Cell Therapy market include target (CD19, BCMA and Others) and indication (Lymphoma, Leukemia and Multiple Myeloma).

Bar chart: Middle East CAR-T Cell Therapy market size, 2024–2034, placeholder estimates. $182.3 Mn in 2024, $227.1 Mn in 2025 and $1.64 Bn in 2034, 24.6% CAGR.
Middle East CAR-T Cell Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Middle East CAR-T Cell Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the CAR-T Cell Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the CAR-T Cell Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for CAR-T Cell Therapy Market in Middle East

The CAR-T Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for CAR-T Cell Therapy Market in Middle East

CAR-T Cell Therapy in Middle East: rules, payment and research

In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)⁠[1] and EDE (UAE)⁠[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)⁠[3] and mandatory health insurance (UAE)⁠[4]. ClinicalTrials.gov lists 10 studies on CAR-T Cell Therapy that are recruiting, active or about to start in Middle East.⁠[5]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Emirates Drug Establishment. Checked 14 Nov 2026.

[3] Council of Health Insurance. Checked 14 Nov 2026.

[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.

[5] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for CAR-T Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in CAR-T Cell Therapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

CAR-T Cell Therapy in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the CAR-T Cell Therapy market in Middle East?
Placeholder estimate: about $227.1 Mn in 2025, rising to about $1.64 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the CAR-T Cell Therapy market in Middle East growing?
Placeholder estimate: about 24.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the CAR-T Cell Therapy market report cover?
The report splits the market by target (CD19, BCMA, Others), indication (Lymphoma, Leukemia, Multiple Myeloma, Autoimmune Diseases) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the CAR-T Cell Therapy market?
Key players include Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb, Johnson & Johnson, Legend Biotech and Autolus Therapeutics.
What is driving the CAR-T Cell Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.
How many clinical trials on CAR-T Cell Therapy are running in Middle East?
10 studies are recruiting, active or about to start in Middle East, counted across the 9 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Middle East. Retrieved 12 Nov 2026.
How much research is published on CAR-T Cell Therapy?
PubMed lists 7,618 papers on CAR-T Cell Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Middle East

See all

Related on cell and gene therapy and oncology

See the topic